Debt-to-equity of Lyell Immunopharma, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Lyell Immunopharma, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • Lyell Immunopharma, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 27%, a 77% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Lyell Immunopharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 27% +12% +77% 30 Sep 2025
Q2 2025 24% +10% +65% 30 Jun 2025
Q1 2025 21% +7% +46% 31 Mar 2025
Q4 2024 18% +5% +34% 31 Dec 2024
Q3 2024 15% +2% +18% 30 Sep 2024
Q2 2024 15% 0% +2.3% 30 Jun 2024
Q1 2024 14% -1% -8.4% 31 Mar 2024
Q4 2023 13% -4% -24% 31 Dec 2023
Q3 2023 13% -7% -35% 30 Sep 2023
Q2 2023 14% -6% -30% 30 Jun 2023
Q1 2023 15% -6% -27% 31 Mar 2023
Q4 2022 18% 31 Dec 2022
Q3 2022 20% 30 Sep 2022
Q2 2022 21% 30 Jun 2022
Q1 2022 21% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.